• Data from the Phase 2 Onvansertib clinical trial will be presented at the 20^th Prostate Cancer Conference.
   
• The trial assesses the efficacies of Onvansertib on patients with Metastatic Castration-Resistant Prostate Cancer.

Trovagene, a clinical-stage oncology therapeutics firm making drugs that specifically target cell division (mitosis), to treat several types of cancer, including leukemia, colorectal and prostate, reportedly announced that latest clinical data from Onvansertib Phase 2 trial, in combination with prednisone/Zytiga® (abiraterone acetate), in metastatic Castration-Resistant Prostate Cancer (mCRPC), will be shown as an oral poster in the Asia-Pacific Prostate Cancer Conference.

This would be the 20^th Prostate Cancer Conference. The conference will be held in Melbourne, Australia from 23^rd Aug to 26^th August of this year.

The information will be given in a moderated, oral poster session. The moderate poster session would take place on 24^th of August in the afternoon at 1:00 (AEDT). Trovagene Poster Presentation would be titled as a Phase 2 Study of a combination of Onvansertib, a PLK1 Inhibitor, with Prednisone and Abiraterone in patients suffering from Metastatic Castration-Resistant Prostate Cancer (mCRPC).

The Abstract number of this presentation is 1044 and the moderate poster session would be coming under the Clinical Urology segment of the presentation. The presentation will be held in the Goldfields Exhibition.

About Trovagene Inc.:

Trovagene is a renowned clinical-stage, oncology therapeutics firm, having a precision cancer medicine based approach to make drugs that specifically target mitosis (cell division) for the treatment of several types of cancer including solid tumors, lymphomas, and leukemias.

Trovagene has proprietary technology and intellectual property that allows the company to examine the circulating tumor DNA (ctDNA) and other clinically actionable markers to recognize patients that are likely to showcase a positive response to specific cancer treatments. Trovagene is aiming to continue the vertical integration of its tumor genomics technology with development of its targeted cancer therapeutics.